Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 01, 2015 1:26 PM ET

Pharmaceuticals

Company Overview of Supernus Pharmaceuticals, Inc.

Company Overview

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical tri...

1550 East Gude Drive

Rockville, MD 20850

United States

Founded in 2005

309 Employees

Phone:

301-838-2500

Key Executives for Supernus Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President, Secretary and Director
Age: 54
Total Annual Compensation: $485.7K
Chief Financial Officer, Principal Accounting Officer and Vice President
Age: 64
Total Annual Compensation: $317.9K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 63
Total Annual Compensation: $342.4K
Chief Scientific Officer and Senior Vice President of Intellectual Property
Age: 58
Total Annual Compensation: $314.8K
Compensation as of Fiscal Year 2014.

Supernus Pharmaceuticals, Inc. Key Developments

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P 1000 Index

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P 1000 Index

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P SmallCap 600 Index

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P SmallCap 600 Index

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P SmallCap 600 Sector Indices – Health Care Sector Index

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to S&P SmallCap 600 Sector Indices – Health Care Sector Index

Similar Private Companies By Industry

Company Name Region
Actient Pharmaceuticals, LLC United States
Octamer Inc. United States
HNP Pharmaceuticals United States
FluGen, Inc. United States
Gliacure, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Supernus Pharmaceuticals, Inc., please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.